NCT01448044 - Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

January 31, 2014

Conditions

Hepatitis C

Interventions

DRUG

BMS-790052 (NS5A Replication Complex Inhibitor)

DRUG

Placebo matching BMS-790052

DRUG

Pegylated-interferon alfa 2a

DRUG

Ribavirin

Trial Locations (26)

10126

Local Institution, Torino

13285

Local Institution, Marseille

15706

Local Institution, A Coruña

22003

Metropolitan Research, Annandale

28046

Local Institution, Madrid

31059

Local Institution, Toulouse

45067

Local Institution, Orléans

54639

Local Institution, Thesaloniki

67091

Local Institution, Strasbourg

75013

Local Institution, Paris

75475

Local Institution, Paris

85925

Local Institution, La Roche-sur-Yon

92673

Scti Research Foundation, San Clemente

93143

Local Institution, Bondy

94000

Local Institution, Créteil

94804

Local Institution, Villejuif

01655

Umass Memorial Medical Center, Worcester

02905

University Gastroenterology, Providence

06202

Local Institution, Nice

00149

Local Institution, Roma

00927

Local Institution, San Juan

08003

Local Institution, Barcelona

08035

Local Institution, Barcelona

SE5 9RS

Local Institution, London

SW17 0QT

Local Institution, London

W2 1NY

Local Institution, London